FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC files second amicus brief saying use of risk management programs to impede generic competition could violate antitrust laws; commission launched an investigation of Celgene four years ago.